Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

3 results

  • Delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • Dovato

    (dolutegravir sodium and lamivudine)
    ViiV Healthcare Company
    Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

  • Triumeq

    (abacavir sulfate, dolutegravir sodium, lamivudine)
    ViiV Healthcare Company
    Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.